Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel oral antivirals in areas of high unmet medical need. Chimerix’s proprietary lipid conjugate technology has produced brincidofovir (CMX001), a clinical-stage nucleotide analog, CMX157 (licensed to ContraVir Pharmaceuticals), and other early clinical candidates such as CMX669.
In February 2016, Chimerix presented detailed results from its Phase 3 SUPPRESS trial of brincidofovir for the prevention of cytomegalovirus (CMV) in patients undergoing hematopoietic cell transplantation (HCT). The SUPPRESS trial did not meet the primary endpoint of prevention of clinically significant CMV infection at Week 24 following HCT; however, a clear antiviral effect was seen at the end of the on-treatment period at Week 14. The SUPPRESS trial also demonstrated no evidence of myelotoxicity or nephrotoxicity among patients treated with brincidofovir. Chimerix will discuss the SUPPRESS data in full with the U.S. Food and Drug Administration (FDA) and foreign regulators, including the benefit-to-risk profile in specific sub-populations, to determine next steps.
In September 2015, Chimerix announced an extension of its contract with the Biomedical Advanced Research and Development Authority (BARDA) for the development of the broad spectrum antiviral, brincidofovir, as a medical countermeasure to treat smallpox. This latest contract extension provides an additional $13.0 million to Chimerix for a period of 15 months. The company received an initial award from BARDA in February 2011 to support early research and development of brincidofovir in animal models of smallpox (Contract Number HHSO100201100013C) and received a contract extension of $17.0 million in September 2014.
In August 2015, Chimerix completed enrollment of its AdVise Study, which is evaluating brincidofovir for the treatment of adenovirus infections in pediatric and adult patients. The company is also conducting Study 305 to obtain clinical outcomes data in patients considered matched controls from the same medical centers as AdVise participants.
In June 2015, Chimerix completed a common stock offering with net proceeds of approximately $162 million. We expect to use these proceeds primarily to fund Chimerix’s Phase 3 trials of brincidofovir in kidney transplant recipients, expansion of commercial manufacturing, pre-launch commercial activities, additional research and development programs, and general corporate purposes.